Paris, France, 1 June 2022 – The Congress of European Association for Percutaneous Cardiovascular Interventions (EuroPCR 2022) was held in-person for the first time since the COVID outbreak and MicroPort Scientific Corporation (“MicroPort®”) took the opportunity to introduce its product portfolio to a global audience recently. On location in Paris, MicroPort®, together with its subsidiaries Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort® Coronary”) and Shanghai MicroPort CardioFlow Medtech Corp (“CardioFlow Medtech”), showcased its rapamycin target eluting coronary stent systems Firehawk® and Firehawk Liberty™; Firefighter™ PTCA and NC balloon dilatation catheters; the VitaFlow Liberty™ transcatheter aortic valve and retrievable delivery system; and the MicroPort® Argus™ OCT System endoluminal imaging solution.
MicroPort® held a joint satellite meeting during EuroPCR 2022, chaied by Prof. Andreas Baumbach from the Heart Center of Queen Mary University of London and moderated by Prof. Pieter Smits from Maasstad Ziekenhuis Hospital in Rotterdam, Netherlands. They were joined by an online panel of renowned global experts including Prof. Xu Bo from Fu Wai Hospital and Prof. Liu Wei from Beijing Jishuitan Hospital.
Prof. Tao Ling of Xijing Hospital announced the latest results from the Firehawk® TARGET STEMI OCT China clinical trial. This study is investigating optical coherence tomography (OCT) for patients with high-risk acute ST-elevation myocardial infarction. The 6-month primary endpoint imaging follow-up data suggest that Firehawk® 6-month stent neointimal thickness is as good as the world-leading stent used in the control group during the same period, which provides further evidence that Firehawk® is able to achieve rapid vessel healing with equal or better safety and efficacy in a high-risk complex patient population combined with world-leading low drug loading, around one-third the amount of similar products..
During the discussion session, Prof. Pieter Smits introduced the TARGET FIRST study, which aims to validate the use of short dual-combination antiplatelet therapy for the low-dose Firehawk® to complete revascularization in patients with acute myocardial infarction. The study will be completed at 40 centers in 6 countries, with enrollment expected to be completed in the third quarter of 2023.
Director Yundai Chen from the 301 General Hospital presented progress from the R-ONE® vascular interventional robot (“R-ONE®”) clinical study in China. Based on the challenges of traditional Percutaneous Coronary Intervention (PCI) and the overall progress of robotic PCI, this important study demonstrates the effectiveness and safety of the R-ONE® vascular interventional navigation control system. The vascular interventional robot improves positioning accuracy, reduces operator error, and reduces radiation exposure hazards without compromising patient safety and procedure effectiveness. Last November, Shanghai MicroPort MedBot (Group) Co. Ltd. (“MicroPort® MedBot®”) established Cathbot (Shanghai) Robot Co., Ltd. with the French company Robocash S.A.S., to deepen MicroPort®’s MedBot®’s efforts on the pan-vascular robotics development. With the clinical study and subsequent market launch once the R-ONE® robotic system is licensed, it is expected that the gap in the field of percutaneous coronary interventional robots in China can be filled, a real benefit to both doctors and patients.
In addition to the meeting, many international cardiologists visited the MicroPort® exhibition booth at the venue, ably supported on site by the MicroPort® CRM team in France. Through this conference, MicroPort® once again presented its diverse product lines to global experts. The unique technology in MicroPort® products is sure to expand the choices and confidence of patients and doctors because of the great benefits for coronary artery disease.
About Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the Future, MicoPort® will continue to steadily promote the target global clinical research program, enrich the cardiovascular interventional therapy product line with the support of accumulated clinical research data, and provide patients with more high-quality and inclusive integrated solutions.